Randomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes

Cited 15 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorY Y Cho-
dc.contributor.authorN I Baek-
dc.contributor.authorH G Chung-
dc.contributor.authorTae Sook Jeong-
dc.contributor.authorK T Lee-
dc.contributor.authorS M Jeon-
dc.contributor.authorH J Kim-
dc.contributor.authorR A McGregor-
dc.contributor.authorM S Choi-
dc.date.accessioned2017-04-19T09:34:05Z-
dc.date.available2017-04-19T09:34:05Z-
dc.date.issued2012-
dc.identifier.issn1876-3820-
dc.identifier.uri10.1016/j.eujim.2012.01.009ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/10966-
dc.description.abstractIntroduction: Alternative complementary therapy with medicinal herbs may help restore normal fasting glycemia in pre-diabetes and therefore delay or prevent T2D. The aim of this randomized controlled trial was to assess the efficacy of Sajabalssuk (Artemisia princeps Pampanini) extract to improve fasting glycemia in pre-diabetes. Methodology: Ninety-nine subjects with pre-diabetes (100. mg/dL. <. impaired fasting glucose. <. 125. mg/dL) were randomly assigned into placebo (starch, 2000. mg/day), positive-control (pinitol, 1140. mg/day), and SBE (Sajabalssuk extract 3000. mg/day) groups for 9. weeks. Primary outcomes were fasting blood glucose and HbA1c. Secondary outcomes were insulin resistance, plasma lipid profile and body composition. Dietary intake was also analyzed, and safety was assessed with plasma liver toxicology markers. Results: Nine weeks of SBE treatment significantly lowered fasting blood glucose (-16.51. ±. 2.78%, p<. 0.05) compared placebo or positive-control, effectively restoring normal fasting glycemia. Furthermore, SBE treatment significantly reduced HbA1c (-7.81. ±. 3.39%, p<. 0.05) and insulin resistance (-14.71. ±. 20.37%, p<. 0.05) compared to placebo or positive-control treatment. In addition, SBE treatment improved non-HDL-cholesterol (-11.57. ±. 3.94%, p<. 0.05) and HDL-cholesterol (10.90. ±. 4.35%, p<. 0.05) compared to placebo and positive-control. However, SBE treatment had no effect on other secondary outcomes including atherogenic biomarkers, blood pressure and body composition. Finally, plasma liver toxicology markers were unaltered by SBE treatment. Conclusions: Pre-diabetes treatment with the medicinal herb Sajabalssuk (3000. mg/day) for 9. weeks can improve fasting blood glucose, HbA1c and reduce insulin resistance. SBE treatment appears to have a secondary benefit leading to improved plasma non-HDL and HDL-cholesterol levels. In conclusion, Sajabalssuk extract may provide a useful alternative therapy for management of pre-diabetes.-
dc.publisherElsevier-
dc.titleRandomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes-
dc.title.alternativeRandomized controlled trial of Sajabalssuk (Artemisia princeps Pampanini) to treat pre-diabetes-
dc.typeArticle-
dc.citation.titleEuropean Journal of Integrative Medicine-
dc.citation.number3-
dc.citation.endPagee308-
dc.citation.startPagee299-
dc.citation.volume4-
dc.contributor.affiliatedAuthorTae Sook Jeong-
dc.contributor.alternativeName조윤영-
dc.contributor.alternativeName백남인-
dc.contributor.alternativeName정해곤-
dc.contributor.alternativeName정태숙-
dc.contributor.alternativeName이경태-
dc.contributor.alternativeName전선민-
dc.contributor.alternativeName김혜진-
dc.contributor.alternativeNameMcGregor-
dc.contributor.alternativeName최명숙-
dc.identifier.bibliographicCitationEuropean Journal of Integrative Medicine, vol. 4, no. 3, pp. e299-e308-
dc.identifier.doi10.1016/j.eujim.2012.01.009-
dc.subject.keywordArtemisia princeps Pampanini-
dc.subject.keywordFasting blood glucose-
dc.subject.keywordHbA1c-
dc.subject.keywordHOMA-IR-
dc.subject.keywordPinitol-
dc.subject.keywordRandomized controlled trial-
dc.subject.localArtemisia princeps Pampanini-
dc.subject.localartemisia princeps Pampanini-
dc.subject.localartemisia princeps pampanini-
dc.subject.localartemisia princeps PAMPANINI-
dc.subject.localfasting blood glucose-
dc.subject.localFasting blood glucose-
dc.subject.localHbA1c-
dc.subject.localHOMA-IR-
dc.subject.localPinitol-
dc.subject.localRandomized controlled trial-
dc.description.journalClassY-
Appears in Collections:
Division of Biomedical Research > Microbiome Convergence Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.